Skip to main content

Table 5 Mean geometric IC50 values for each component of AL and ASAQ at D0 (before treatment) versus day of treatment failure among treatment participants

From: In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso

Treatment n n P value
IC50 at D0 in nM (IC 95%) IC50 at DoR in nM (IC 95%)  
ASAQ
 MDA 188 33
19.80 (17.83–21.99) 24.94 (20.68–30.08) 0.94
 DHA 190 34
0.85 (0.76–0.95) 0.66 (0.47–0.93) 0.96
AL
 DHA 191 54
0.8 (0.72–0.90) 0.67 (0.54–0.83) 0.43
 LUM 192 53
24.13 (20.45–28.46) 37.07 (28.37–48.44) 0.05
  1. nM nanomolar, DoR day of recurrent parasitaemia, ASAQ amodiaqine–artesunate, AL artemether lumefantrine, MDA monodesethylamodiaquine, DHA dihydroartermisinin, LUM lumefantrine